rs137852259
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000218099.7(F9):c.1136G>A(p.Arg379Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000000911 in 1,098,189 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R379G) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000218099.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F9 | NM_000133.4 | c.1136G>A | p.Arg379Gln | missense_variant | 8/8 | ENST00000218099.7 | NP_000124.1 | |
F9 | NM_001313913.2 | c.1022G>A | p.Arg341Gln | missense_variant | 7/7 | NP_001300842.1 | ||
F9 | XM_005262397.5 | c.1007G>A | p.Arg336Gln | missense_variant | 7/7 | XP_005262454.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F9 | ENST00000218099.7 | c.1136G>A | p.Arg379Gln | missense_variant | 8/8 | 1 | NM_000133.4 | ENSP00000218099 | P1 | |
F9 | ENST00000394090.2 | c.1022G>A | p.Arg341Gln | missense_variant | 7/7 | 1 | ENSP00000377650 | |||
F9 | ENST00000643157.1 | n.1723+80G>A | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 9.11e-7 AC: 1AN: 1098189Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 363551
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Hereditary factor IX deficiency disease Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 11, 2022 | Variant summary: F9 c.1136G>A (p.Arg379Gln) results in a conservative amino acid change located in the Trypsin-like serine protease domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function, while two tools predict the variant to be damaging or disease-causing. The variant was absent in 183173 control chromosomes. c.1136G>A has been reported in the literature in multiple individuals affected with Factor IX Deficiency (Hemophilia B) (e.g. Hamasaki-Katagiri_2012, Yu_2012, Agrawal_2022). These data indicate that the variant is very likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function (e.g. Jin_2004, Mathur_1999). The most pronounced variant effect results in <10% of normal activity. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 1988 | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 26, 2018 | The F9 c.1136G>A; p.Arg379Gln variant (rs137852259), also known as p.Arg333Gln or 31119G>A in traditional nomenclature, is reported in the literature in multiple individuals and families affected with moderate to severe hemophilia B (Chavali 2009, Hamasaki-Katagiri 2012, Lin 2018, Factor IX database and references therein). This variant is reported in ClinVar (Variation ID: 10613), and is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. Additionally, other variants at this codon (p.Arg379Gly/Pro/Leu) have been reported in individuals with moderate to severe hemophilia B (Factor IX database and references therein). The arginine at codon 379 is highly conserved, but computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Based on available information, this variant is considered to be pathogenic. References: Link to Factor IX database: http://www.factorix.org/ Chavali S et al. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics. 2009 Dec;94(6):433-7. Hamasaki-Katagiri N et al. Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia. 2012 Nov;18(6):933-40. Lin XY et al. Establishing a comprehensive genetic diagnosis strategy for hemophilia B and its application in Chinese population. Int J Lab Hematol. 2018 Apr;40(2):215-228. - |
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 04, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg379 amino acid residue in F9. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19699296). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt F9 protein function. ClinVar contains an entry for this variant (Variation ID: 10613). This variant is also known as p.Arg333Gln. This missense change has been observed in individuals with hemophilia B (PMID: 22639855). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 379 of the F9 protein (p.Arg379Gln). - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 05, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as p.R333Q; This variant is associated with the following publications: (PMID: 34590426, 31064749, 22639855, 23683414, 29274203, 34272389, 28270892, 37445943, 15178576, 38783919, 34626083, 33760382, 28193338, 3181127, 17066096, 2270538, 8257988, 30992271, 27766048, 19699296, 10373456, 30771412) - |
Hereditary factor VIII deficiency disease Pathogenic:1
Pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Feb 01, 2019 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at